---
reference_id: "PMID:41154810"
title: "Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications."
authors:
- El Motassime A
- Vitiello R
- Comodo RM
- Capece G
- Bocchino G
- Bocchi MB
- Maccauro G
- Meschini C
journal: Biology (Basel)
year: '2025'
doi: 10.3390/biology14101407
content_type: abstract_only
---

# Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications.
**Authors:** El Motassime A, Vitiello R, Comodo RM, Capece G, Bocchino G, Bocchi MB, Maccauro G, Meschini C
**Journal:** Biology (Basel) (2025)
**DOI:** [10.3390/biology14101407](https://doi.org/10.3390/biology14101407)

## Content

1. Biology (Basel). 2025 Oct 13;14(10):1407. doi: 10.3390/biology14101407.

Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic 
Implications.

El Motassime A(1)(2), Vitiello R(1)(2), Comodo RM(1)(2)(3), Capece G(1)(2)(4), 
Bocchino G(1)(2), Bocchi MB(1)(2), Maccauro G(1)(2), Meschini C(1).

Author information:
(1)Department of Orthopedics and Geriatric Sciences, Catholic University of the 
Sacred Heart, 00168 Rome, Italy.
(2)Department of Orthopedics and Rheumatological Sciences, Fondazione 
Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
(3)Department of Orthopaedics, Mater Olbia Hospital, Strada Statale 125 
Orientale Sarda, 07026 Olbia, Italy.
(4)U.O.C. Orthopedics and Traumatology, Ospedale dei Pellegrini, 80134 Naples, 
Italy.

Osteosarcoma (OS) is the most common primary malignant bone tumor, predominantly 
affecting adolescents and young adults. Despite advances in surgery and 
multi-agent chemotherapy, survival rates for metastatic or recurrent OS remain 
poor, highlighting the need for novel prognostic and therapeutic strategies. 
This review integrates histopathologic, molecular, and immune perspectives to 
provide a comprehensive understanding of OS biology in the context of precision 
medicine. We discuss classic morphologic and radiographic features alongside 
recent insights into the tumor microenvironment, including the role of 
tumor-infiltrating lymphocytes, tumor-associated macrophages, and immune 
checkpoint expression. Emerging molecular markers, such as gene expression-based 
immune risk signatures, circulating tumor DNA, and gasdermin D overexpression, 
are evaluated for their prognostic and therapeutic relevance. Key dysregulated 
pathways, including WNT/Î²-catenin and JAK/STAT, are examined in relation to 
metastasis, chemoresistance, and immune evasion, with emphasis on current 
targeted approaches under development. By bridging histopathology, 
immunogenomics, and translational research, this work outlines how integrated 
biomarker assessment can refine patient stratification and guide the 
implementation of individualized treatment strategies in OS.

DOI: 10.3390/biology14101407
PMCID: PMC12561861
PMID: 41154810

Conflict of interest statement: The authors declare no conflicts of interest.